A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2004
12/16/2004	WO2004108155A1 Cells used as carriers for bacteria
12/16/2004	WO2004108154A1 Prevention of pulmonary immunopathology using mutant bacterial toxins
12/16/2004	WO2004108145A1 Therapeutical composition containing dentritic cells and use thereof
12/16/2004	WO2004108100A1 Compositions and method for promoting the growth of human hair
12/16/2004	WO2004108072A2 Delivery of immune response modifier compounds using metal-containing particulate support materials
12/16/2004	WO2004108070A2 Releasable polymeric conjugates based on aliphatic biodegradable linkers
12/16/2004	WO2004096844A3 Group 1 mite polypeptide variants
12/16/2004	WO2004084936A8 Modified free-living microbes, vaccine compositions and methods of use thereof
12/16/2004	WO2004081198A3 Methods for modulating angiogenesis with apelin compositions
12/16/2004	WO2004061423A3 Compositions and methods for diagnosing and treating colon cancers
12/16/2004	WO2004039417A3 Drying process
12/16/2004	WO2004000872A9 Improved alphavirus vectors having attenuated virion structural proteins
12/16/2004	WO2003092582B1 Chimeric ebola virus envelopes and uses therefor
12/16/2004	WO2003027254A3 15625 receptor, a novel g-protein coupled receptor
12/16/2004	WO2003005953A3 Viral proteins capable of binding lar
12/16/2004	WO2002070665A8 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
12/16/2004	US20040254365 administering a fusion polypeptide including a signal peptide and a part of an envelope protein of the flavivirus; or an expression vector containing a nucleic acid encoding the fusion polypeptide; vaccines
12/16/2004	US20040254354 Extracellular matrix-binding proteins from Staphylococcus aureus
12/16/2004	US20040254349 Mycobacterial antigens expressed under low oxygen tension
12/16/2004	US20040254144 Use of inhibitors of heparin-binding epidermal growth factor or inhibitors of its receptors for the preparation of drugs useful for treating myeloma
12/16/2004	US20040254130 Chlamydia antigens and corresponding dna fragments and uses thereof
12/16/2004	US20040253730 Identifying modulators which induce apoptosis and activate cell cycle checkpoint systems; for use in treatment and prevention of cell proliferative disorders
12/16/2004	US20040253722 Process for the maturation of dentritic cells and a vaccine
12/16/2004	US20040253711 Mycobacterial genes down-regulated during latency
12/16/2004	US20040253710 Transgenic escherichia for which express bacterial surface protein for use in generation of vaccine which prevents coliform bacterial infection; antidiarrhea agents
12/16/2004	US20040253698 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
12/16/2004	US20040253683 Cryptopain compositions for prophylaxis, treatment, diagnosis and detection of cryptosporidium species
12/16/2004	US20040253674 Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
12/16/2004	US20040253673 Recombinant botulinum toxins with a soluble C-terminal portion
12/16/2004	US20040253651 Detected from secreted glycoprotein (such as matrix metalloproteinases, prostate specific antigen, kallikrein 2, human chorionic gonadotrophin or carcinoembryonic antigen); glycosyltransferases; for diagnosing and targeting cell proliferative disorders; vaccines
12/16/2004	US20040253611 Immunologically active proteins from borrelia burgdorferi
12/16/2004	US20040253610 Expression vector comprising nucleotide sequences coding tumor necrosis factor receptor protein (TWEAK) for use in identifying modulators for treatment of inflammatory, cardiovacullar, vision and cancer disorders
12/16/2004	US20040253599 Novel protein, its dna and use thereof
12/16/2004	US20040253580 Nucleotide sequences coding viral protein for use in treatment and prevention of viral disease in fish; veterinary medicine
12/16/2004	US20040253574 Method for producing ready to use, antigen loaded or unloaded, cryconserved mature dendritic cells
12/16/2004	US20040253316 Production scale method of forming microparticles
12/16/2004	US20040253271 Live attenuated viral vaccines for Eastern equine encephalitis virus
12/16/2004	US20040253270 Nucleic acid encoding infectious, nonpathogenic porcine circovirus type-1(PCV1), which contains immunogenic open reading frame gene of pathogenic PCV2 in place of an ORF gene of PCV1 nucleic acid molecule; means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome
12/16/2004	US20040253249 Pulsatile transdermally administered antigens and adjuvants
12/16/2004	US20040253247 Conjugate comprising a peptide having an engineered amino acid sequence capable of binding a plasma protein, said peptide conjugated to the therapeutic or diagnostic substance, wherein elimination half time of conjugate exceeds that of unconjugated therapeutic or diagnostic substance; peptide ligands
12/16/2004	US20040253245 Modulating an immune response by administering a modulator of Notch intracellular domain protease activity, including modulators of presenilin and presenilin-dependent gamma secretase activity; immunotherapy; treatment of Alzheimer's disease
12/16/2004	US20040253244 Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
12/16/2004	US20040253243 polynucleotides capable of binding to cytokines, growth factors and cell surface proteins, used for prophylaxis of vision disorders
12/16/2004	US20040253242 immunoglobulins or fragments comprising complementarity determining regions (CDR) having segments replaced with human brain natriuretic peptides, glucagon-like peptides, exendins, glucagons, pituitary adenylate cyclase-activating polypeptides and/or mimetics; immunotherapy
12/16/2004	US20040253241 Inducible ligand for alpha1beta1 integrin and uses
12/16/2004	US20040253240 immunogens used to induce immune response against specific epitopes of apolipoproteins; prophylaxis of atherosclerosis; immunotherapy
12/16/2004	US20040253235 administering interferon-beta (IFN- beta) receptor agonist and tumor associated antigen to increase an immune response against the tumor cells
12/16/2004	US20040253233 genetic engineered chimeric and humanized antibodies obtained from murine monoclonal antibody P3 (MAb P3) and its antiidiotypic antibodies, used as antitumor agents
12/16/2004	US20040253232 monoclonal antibodies or antigen binding fragments that specifically to six transmembrane epithelial antigens of the prostate (STEAP-1), used for medical diagnosis, prognosis, prophylaxis and/or therapy for cancers
12/16/2004	US20040253231 monoclonal or polyclonal antibodies having specific reactivity with adenosine triphosphate binding domains, caspase recruitment domains and triosephosphate isomerase domain peptides, used for modulation of apoptosis
12/16/2004	US20040253229 administering a mixture of carriers and drugs that modulate signal transduction mediated by activation inducible lymphocyte immunomodulatory molecule (AILIM); immunosuppressants
12/16/2004	US20040253228 concurrently administering complexes of antigenic proteins or peptides; antimetastasis agents
12/16/2004	US20040253222 transgenic neisseria having mutant phospholipase gene so that the bacteria has reduced phospholipase D activity as compared wild-type; polypeptide and polynucleotide, used for immunization of mammals against bacterial infections
12/16/2004	US20040253218 Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease
12/16/2004	US20040253216 Activated checkpoint therapy and methods of use thereof
12/16/2004	US20040253210 replication-defective adenovirus type 7 that expresses one or more HIV polypeptides for use in stimulating an immune response to HIV-1; adenovirus serotype 7 cosmid vector; gene therapy
12/16/2004	US20040253208 Interleukin-1 muteins useful as vaccine adjuvants
12/16/2004	CA2531569A1 Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survivial of transplanted hematopoietic stemcell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transformation introducing the gene
12/16/2004	CA2528851A1 Extracellular aspergillus polypeptides
12/16/2004	CA2528727A1 Immunomodulating compositions, uses therefor and processes for their production
12/16/2004	CA2528136A1 Transfection agents
12/16/2004	CA2527726A1 De-immunized anti-cd3 antibody
12/16/2004	CA2527346A1 Cell surface expression vector of sars virus antigen and microorganisms transformed thereby
12/16/2004	CA2526789A1 Cells used as carriers for bacteria
12/16/2004	CA2526669A1 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
12/16/2004	CA2526509A1 Connective tissue growth factor antibodies
12/16/2004	CA2526007A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers
12/16/2004	CA2525975A1 Humanized antibodies that recognize beta amyloid peptide
12/16/2004	CA2524910A1 Therapeutical composition containing dendritic cells and use thereof
12/16/2004	CA2524329A1 Anti-hgf-r antibodies and their use
12/16/2004	CA2521682A1 Delivery of immune response modifier compounds using metal-containing particulate support materials
12/15/2004	EP1486505A1 Angiotensin derivatives
12/15/2004	EP1486215A2 Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
12/15/2004	EP1486211A1 Compositions for treating cancer using viruses
12/15/2004	EP1485497A2 Ricin vaccine and methods of making and using thereof
12/15/2004	EP1485488A2 Recombinant negative strand virus rna expression systems and vaccines
12/15/2004	EP1485484A2 Antigen fragments for the diagnosis of toxoplasma gondii
12/15/2004	EP1485477A2 Novel type-1 cytokine receptor glm-r
12/15/2004	EP1485469A2 Virus like particle from papillomavirus and their use in vaccine
12/15/2004	EP1485468A2 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
12/15/2004	EP1485466A2 Methods for treating diseases or conditions with peptide constructs
12/15/2004	EP1485403A2 Compositions and methods to initiate or enhance antibody and major-histocompatibility class i or class ii-restricted t cell responses by using immunomodulatory, non-coding rna motifs
12/15/2004	EP1485130A2 Reagents and treatment methods for autoimmune diseases
12/15/2004	EP1485127A2 Administration of agents for the treatment of inflammation
12/15/2004	EP1485126A2 Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
12/15/2004	EP1485125A1 Improvements in vaccination
12/15/2004	EP1485124A2 Method of inducing an enhanced immune response against hiv
12/15/2004	EP1485123A2 Method of inducing an enhanced immune response against hiv
12/15/2004	EP1485122A2 Novel application of vaccination against tnf-alpha
12/15/2004	EP1485075A2 Mhc-peptide complex binding ligands
12/15/2004	EP1485070A1 Pharmaceutical microparticles
12/15/2004	EP1263779B1 Self antigen vaccines for treating b cell lymphomas and other cancers
12/15/2004	EP1259248B1 Methods for treating cancers expressing vascular endothelial growth factor d
12/15/2004	EP1221937B1 Hybrid matrices and hybrid matrix mixtures
12/15/2004	EP1212358B1 Synthetic papillomavirus genes optimized for expression in human cells
12/15/2004	EP1207899B1 Treatment of allergic rhinitis with certain vasoactive amine binding proteins
12/15/2004	EP1073461B1 Viral chimeras comprised of caev and hiv-1 genetic elements
12/15/2004	EP1025211B1 Hyaluronan synthase gene and uses thereof
12/15/2004	EP1017283B1 Polynucleotide vaccine formulations
12/15/2004	EP1015025B1 T-cell vaccination for the treatment of multiple sclerosis

1 ... 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 ... 1823